Search

Your search keyword '"Schlichting, Ellen"' showing total 383 results
Start Over Author "Schlichting, Ellen"
383 results on '"Schlichting, Ellen"'

2. Deep learning for automated scoring of immunohistochemically stained tumour tissue sections – Validation across tumour types based on patient outcomes

Author

Bathen, Tone F., Borgen, Elin, Børresen-Dale, Anne-Lise, Engebråten, Olav, Fritzman, Britt, Hartman-Johnsen, Olaf Johan, Garred, Øystein, Geisler, Jürgen, Geitvik, Gry Aarum, Hofvind, Solveig, Kåresen, Rolf, Langerød, Anita, Lingjærde, Ole Christian, Mælandsmo, Gunhild M., Naume, Bjørn, Russnes, Hege G., Sahlberg, Kristine Kleivi, Sauer, Torill, Skjerven, Helle Kristine, Schlichting, Ellen, Sørlie, Therese, Kildal, Wanja, Cyll, Karolina, Kalsnes, Joakim, Islam, Rakibul, Julbø, Frida M., Pradhan, Manohar, Ersvær, Elin, Shepherd, Neil, Vlatkovic, Ljiljana, Tekpli, Xavier, Kristensen, Gunnar B., Askautrud, Hanne A., Hveem, Tarjei S., and Danielsen, Håvard E.

Published
2024
Full Text
View/download PDF

5. Brystkreft under graviditet.

Author

VANDRAAS, KATHRINE, REINERTSEN, KRISTIN VALBORG, GUDIM, HILDE BEATE, BOWEN, CAMILL AANETTE, GJERDALEN, GURI, SCHLICHTING, ELLEN, NAUME, BJØRN, and SÆTERSDAL, ANNA

Published
2024
Full Text
View/download PDF

10. 'It was an important part of my treatment': a qualitative study of Norwegian breast Cancer patients' experiences with mainstreamed genetic testing

Author

Stramsvik, Nina, Olsson, Pernilla, Gravdehaug, Berit, Lurås, Hilde, Schlichting, Ellen, Jargensen, Kjersti, Wangensteen, Teresia, Vamre, Tone, Heramb, Cecilie, Maehle, Lovise, and Grindedal, Eli Marie

Subjects
Oncology, Experimental -- Analysis, Medical tests -- Analysis, Health care industry -- Analysis, Cancer -- Care and treatment -- Research, Medical genetics -- Analysis, Breast cancer -- Care and treatment, Genetic screening -- Analysis, Health care industry, Health
Abstract

Background In South-Eastern Norway, genetic testing for BRCA1 and BRCA2 is offered to breast cancer patients by their treating surgeon or oncologist. Genetic counselling from a geneticist or a genetic counsellor is offered only to those who test positive for a pathogenic variant or have a family history of cancer. This practice is termed 'mainstreamed genetic testing'. The aim of this study was to learn about patients' experience of this healthcare service. Methods Qualitative in-depth interviews were conducted with 22 breast cancer patients who had been diagnosed during the first half of 2016 or 2017 at one regional and one university hospital and who had been offered testing by their treating physician. A six-phase thematic approach was used to analyse the data. Results The participants had varied experiences of how and when testing was offered. Three main themes emerged from the analysis: 1. informational and communicational needs and challenges during a chaotic time, 2. the value of genetic testing and 3. the importance of standardised routines for mainstreamed genetic testing. Conclusions Despite the shock of their diagnosis and the varying experiences they had in respect of how and when testing was offered, all of the participants emphasised that genetic testing had been an important part of their diagnosis and treatment. Our results indicate that there is a need for continuous collaboration between geneticists, surgeons, oncologists and laboratory specialists in order to establish simple and robust routines so as to ensure that all eligible breast cancer patients are offered testing at a point when the test result can have an impact on treatment. Keywords: Breast cancer, BRCA1, BRCA2, Mainstreamed genetic testing, Qualitative study, Genetic testing for breast cancer, Author(s): Nina Stramsvik[sup.1,2], Pernilla Olsson[sup.3], Berit Gravdehaug[sup.4], Hilde Lurås[sup.5,6], Ellen Schlichting[sup.7], Kjersti Jargensen[sup.8], Teresia Wangensteen[sup.8], Tone Vamre[sup.8], Cecilie Heramb[sup.8], Lovise Maehle[sup.8] and Eli Marie Grindedal[sup.8] Background Women with inherited pathogenic [...]

Published
2022
Full Text
View/download PDF

11. The prognostic significance of tumor cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients

Author

Molloy, Timothy J, Bosma, Astrid J, Baumbusch, Lars O, Synnestvedt, Marit, Borgen, Elin, Russnes, Hege, Schlichting, Ellen, van't Veer, Laura J, and Naume, Bjørn

Abstract

Abstract Introduction The detection of circulating tumour cells (CTCs) in the peripheral blood and disseminated tumour cells (DTCs) in the bone marrow are promising prognostic tools for risk stratification in early breast cancer. There is, however, a need for further validation of these techniques in larger patient cohorts with adequate follow-up periods. Methods We assayed CTCs and DTCs at primary surgery in 733 stage I or II breast cancer patients with a median follow-up time of 7.6 years. CTCs were detected in samples of peripheral blood mononuclear cells previously stored in liquid-nitrogen using a previously-developed multi-marker quantitative PCR (QPCR)-based assay. DTCs were detected in bone marrow samples by immunocytochemical analysis using anti-cytokeratin antibodies. Results CTCs were detected in 7.9% of patients, while DTCs were found in 11.7%. Both CTC and DTC positivity predicted poor metastasis-free survival (MFS) and breast cancer-specific survival (BCSS); MFS hazard ratio (HR) = 2.4 (P < 0.001)/1.9 (P = 0.006), and BCSS HR = 2.5 (P < 0.001)/2.3 (P = 0.01), for CTC/DTC status, respectively). Multivariate analyses demonstrated that CTC status was an independent prognostic variable for both MFS and BCSS. CTC status also identified a subset of patients with significantly poorer outcome among low-risk node negative patients that did not receive adjuvant systemic therapy (MFS HR 2.3 (P = 0.039), BCSS HR 2.9 (P = 0.017)). Using both tests provided increased prognostic information and indicated different relevance within biologically dissimilar breast cancer subtypes. Conclusions These results support the use of CTC analysis in early breast cancer to generate clinically useful prognostic information.

Published
2011

13. Abstract 2170: Pre-treatment protein landscape in HER2-negative breast cancer treated with carboplatin in a neoadjuvant chemotherapy setting

Author

Dahle, Maria Aanesland, primary, Egeland, Eivind Valen, additional, Prasmickaite, Lina, additional, Lingjærde, Ole Christian, additional, Russnes, Hege, additional, Garred, Øystein, additional, Smebye, Marianne L., additional, Skjerven, Helle, additional, Schlichting, Ellen, additional, Naume, Bjørn, additional, Mælandsmo, Gunhild, additional, Engebraaten, Olav, additional, and Haugen, Mads H., additional

Published
2023
Full Text
View/download PDF

14. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry

Author

Mueller, Stefanie H., Lai, Alvina G., Valkovskaya, Maria, Michailidou, Kyriaki, Bolla, Manjeet K., Wang, Qin, Dennis, Joe, Lush, Michael, Abu-Ful, Zomoruda, Ahearn, Thomas U., Andrulis, Irene L., Anton-Culver, Hoda, Antonenkova, Natalia N., Arndt, Volker, Aronson, Kristan J., Augustinsson, Annelie, Baert, Thais, Freeman, Laura E.Beane, Beckmann, Matthias W., Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Blomqvist, Carl, Bogdanova, Natalia V., Bojesen, Stig E., Bonanni, Bernardo, Brenner, Hermann, Brucker, Sara Y., Buys, Saundra S., Castelao, Jose E., Chan, Tsun L., Chang-Claude, Jenny, Chanock, Stephen J., Choi, Ji Yeob, Chung, Wendy K., Sahlberg, Kristine K., Børresen-Dale, Anne Lise, Ottestad, Lars, Kåresen, Rolf, Schlichting, Ellen, Holmen, Marit Muri, Sauer, Toril, Haakensen, Vilde, Engebråten, Olav, Naume, Bjørn, Fosså, Alexander, Riis, Margit, Flyger, Henrik, Gao, Yu Tang, Scott, Christopher, Mueller, Stefanie H., Lai, Alvina G., Valkovskaya, Maria, Michailidou, Kyriaki, Bolla, Manjeet K., Wang, Qin, Dennis, Joe, Lush, Michael, Abu-Ful, Zomoruda, Ahearn, Thomas U., Andrulis, Irene L., Anton-Culver, Hoda, Antonenkova, Natalia N., Arndt, Volker, Aronson, Kristan J., Augustinsson, Annelie, Baert, Thais, Freeman, Laura E.Beane, Beckmann, Matthias W., Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Blomqvist, Carl, Bogdanova, Natalia V., Bojesen, Stig E., Bonanni, Bernardo, Brenner, Hermann, Brucker, Sara Y., Buys, Saundra S., Castelao, Jose E., Chan, Tsun L., Chang-Claude, Jenny, Chanock, Stephen J., Choi, Ji Yeob, Chung, Wendy K., Sahlberg, Kristine K., Børresen-Dale, Anne Lise, Ottestad, Lars, Kåresen, Rolf, Schlichting, Ellen, Holmen, Marit Muri, Sauer, Toril, Haakensen, Vilde, Engebråten, Olav, Naume, Bjørn, Fosså, Alexander, Riis, Margit, Flyger, Henrik, Gao, Yu Tang, and Scott, Christopher

Abstract

Background: Low-frequency variants play an important role in breast cancer (BC) susceptibility. Gene-based methods can increase power by combining multiple variants in the same gene and help identify target genes. Methods: We evaluated the potential of gene-based aggregation in the Breast Cancer Association Consortium cohorts including 83,471 cases and 59,199 controls. Low-frequency variants were aggregated for individual genes’ coding and regulatory regions. Association results in European ancestry samples were compared to single-marker association results in the same cohort. Gene-based associations were also combined in meta-analysis across individuals with European, Asian, African, and Latin American and Hispanic ancestry. Results: In European ancestry samples, 14 genes were significantly associated (q < 0.05) with BC. Of those, two genes, FMNL3 (P = 6.11 × 10−6) and AC058822.1 (P = 1.47 × 10−4), represent new associations. High FMNL3 expression has previously been linked to poor prognosis in several other cancers. Meta-analysis of samples with diverse ancestry discovered further associations including established candidate genes ESR1 and CBLB. Furthermore, literature review and database query found further support for a biologically plausible link with cancer for genes CBLB, FMNL3, FGFR2, LSP1, MAP3K1, and SRGAP2C. Conclusions: Using extended gene-based aggregation tests including coding and regulatory variation, we report identification of plausible target genes for previously identified single-marker associations with BC as well as the discovery of novel genes implicated in BC development. Including multi ancestral cohorts in this study enabled the identification of otherwise missed disease associations as ESR1 (P = 1.31 × 10−5), demonstrating the importance of diversifying study cohorts.

Published
2023

15. Breast cancer quantitative proteome and proteogenomic landscape

Author

Johansson, Henrik J., Socciarelli, Fabio, Vacanti, Nathaniel M., Haugen, Mads H., Zhu, Yafeng, Siavelis, Ioannis, Fernandez-Woodbridge, Alejandro, Aure, Miriam R., Sennblad, Bengt, Vesterlund, Mattias, Branca, Rui M., Orre, Lukas M., Huss, Mikael, Fredlund, Erik, Beraki, Elsa, Garred, Øystein, Boekel, Jorrit, Sauer, Torill, Zhao, Wei, Nord, Silje, Höglander, Elen K., Jans, Daniel C., Brismar, Hjalmar, Haukaas, Tonje H., Bathen, Tone F., Schlichting, Ellen, Naume, Bjørn, Consortia Oslo Breast Cancer Research Consortium (OSBREAC), Luders, Torben, Borgen, Elin, Kristensen, Vessela N., Russnes, Hege G., Lingjærde, Ole Christian, Mills, Gordon B., Sahlberg, Kristine K., Børresen-Dale, Anne-Lise, and Lehtiö, Janne

Published
2019
Full Text
View/download PDF

16. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry

Author

Mueller, Stefanie H, Lai, Alvina G, Valkovskaya, Maria, Michailidou, Kyriaki, Bolla, Manjeet K, Wang, Qin, Dennis, Joe, Lush, Michael, Abu-Ful, Zomoruda, Ahearn, Thomas U, Andrulis, Irene L, Anton-Culver, Hoda, Antonenkova, Natalia N, Arndt, Volker, Aronson, Kristan J, Augustinsson, Annelie, Baert, Thais, Freeman, Laura E Beane, Beckmann, Matthias W, Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Blomqvist, Carl, Bogdanova, Natalia V, Bojesen, Stig E, Bonanni, Bernardo, Brenner, Hermann, Brucker, Sara Y, Buys, Saundra S, Castelao, Jose E, Chan, Tsun L, Chang-Claude, Jenny, Chanock, Stephen J, Choi, Ji-Yeob, Chung, Wendy K, Sahlberg, Kristine K, Børresen-Dale, Anne-Lise, Ottestad, Lars, Kåresen, Rolf, Schlichting, Ellen, Holmen, Marit Muri, Sauer, Toril, Haakensen, Vilde, Engebråten, Olav, Naume, Bjørn, Fosså, Alexander, Kiserud, Cecile E, Reinertsen, Kristin V, Helland, Åslaug, Riis, Margit, Geisler, Jürgen, Grenaker Alnaes, Grethe I, Colonna, Sarah V, Cornelissen, Sten, Couch, Fergus J, Czene, Kamila, Daly, Mary B, Devilee, Peter, Dörk, Thilo, Dossus, Laure, Dwek, Miriam, Eccles, Diana M, Ekici, Arif B, Eliassen, A Heather, Engel, Christoph, Evans, D Gareth, Fasching, Peter A, Fletcher, Olivia, Flyger, Henrik, Gago-Dominguez, Manuela, Gao, Yu-Tang, García-Closas, Montserrat, García-Sáenz, José A, Genkinger, Jeanine, Gentry-Maharaj, Aleksandra, Grassmann, Felix, Guénel, Pascal, Gündert, Melanie, Haeberle, Lothar, Hahnen, Eric, Haiman, Christopher A, Håkansson, Niclas, Hall, Per, Harkness, Elaine F, Harrington, Patricia A, Hartikainen, Jaana M, Hartman, Mikael, Hein, Alexander, Ho, Weang-Kee, Hooning, Maartje J, Hoppe, Reiner, Hopper, John L, Houlston, Richard S, Howell, Anthony, Hunter, David J, Huo, Dezheng, Marsh, Deborah, Scott, Rodney, Baxter, Robert, Yip, Desmond, Carpenter, Jane, Davis, Alison, Pathmanathan, Nirmala, Simpson, Peter, Graham, Dinny, Sachchithananthan, Mythily, Ito, Hidemi, Iwasaki, Motoki, Jakubowska, Anna, Janni, Wolfgang, John, Esther M, Jones, Michael E, Jung, Audrey, Kaaks, Rudolf, Kang, Daehee, Khusnutdinova, Elza K, Kim, Sung-Won, Kitahara, Cari M, Koutros, Stella, Kraft, Peter, Kristensen, Vessela N, Kubelka-Sabit, Katerina, Kurian, Allison W, Kwong, Ava, Lacey, James V, Lambrechts, Diether, Le Marchand, Loic, Li, Jingmei, Linet, Martha, Lo, Wing-Yee, Long, Jirong, Lophatananon, Artitaya, Mannermaa, Arto, Manoochehri, Mehdi, Margolin, Sara, Matsuo, Keitaro, Mavroudis, Dimitrios, Menon, Usha, Muir, Kenneth, Murphy, Rachel A, Nevanlinna, Heli, Newman, William G, Niederacher, Dieter, O’Brien, Katie M, Obi, Nadia, Offit, Kenneth, Olopade, Olufunmilayo I, Olshan, Andrew F, Olsson, Håkan, Park, Sue K, Patel, Alpa V, Patel, Achal, Perou, Charles M, Peto, Julian, Pharoah, Paul DP, Plaseska-Karanfilska, Dijana, Presneau, Nadege, Rack, Brigitte, Radice, Paolo, Ramachandran, Dhanya, Rashid, Muhammad U, Rennert, Gad, Romero, Atocha, Ruddy, Kathryn J, Ruebner, Matthias, Saloustros, Emmanouil, Sandler, Dale P, Sawyer, Elinor J, Schmidt, Marjanka K, Schmutzler, Rita K, Schneider, Michael O, Scott, Christopher, Shah, Mitul, Sharma, Priyanka, Shen, Chen-Yang, Shu, Xiao-Ou, Simard, Jacques, Surowy, Harald, Tamimi, Rulla M, Tapper, William J, Taylor, Jack A, Teo, Soo Hwang, Teras, Lauren R, Toland, Amanda E, Tollenaar, Rob AEM, Torres, Diana, Torres-Mejía, Gabriela, Troester, Melissa A, Truong, Thérèse, Vachon, Celine M, Vijai, Joseph, Weinberg, Clarice R, Wendt, Camilla, Winqvist, Robert, Wolk, Alicja, Wu, Anna H, Yamaji, Taiki, Yang, Xiaohong R, Yu, Jyh-Cherng, Zheng, Wei, Ziogas, Argyrios, Ziv, Elad, Dunning, Alison M, Easton, Douglas F, Hemingway, Harry, Hamann, Ute, Kuchenbaecker, Karoline B, HUS Comprehensive Cancer Center, Department of Oncology, Clinicum, Medicum, University of Helsinki, Department of Obstetrics and Gynecology, HUS Gynecology and Obstetrics, Medical Oncology, Kuchenbaecker, Karoline B [0000-0001-9726-603X], and Apollo - University of Cambridge Repository

Subjects
Genome-wide association study, Black People, Breast Neoplasms/genetics, VARIANTS, PHENOTYPE, Polymorphism, Single Nucleotide, SDG 3 - Good Health and Well-being, Genetics, Humans, Genetic Predisposition to Disease, ddc:610, Genetic Testing, GENOME-WIDE ASSOCIATION, Molecular Biology, Genetics (clinical), Medicinsk genetik, Genetics & Heredity, RISK, Science & Technology, Breast cancer susceptibility, Manchester Cancer Research Centre, IDENTIFICATION, HERITABILITY, Diverse ancestry, ResearchInstitutes_Networks_Beacons/mcrc, Research, 1184 Genetics, developmental biology, physiology, PATHWAYS, Rare variants, Formins/genetics, LIGASE CBL-B, Gene regulation, METASTASIS, Genome-Wide Association Study/methods, Molecular Medicine, Female, Medical Genetics, Life Sciences & Biomedicine, FUNCTIONAL ANNOTATION
Abstract

Background Low-frequency variants play an important role in breast cancer (BC) susceptibility. Gene-based methods can increase power by combining multiple variants in the same gene and help identify target genes. Methods We evaluated the potential of gene-based aggregation in the Breast Cancer Association Consortium cohorts including 83,471 cases and 59,199 controls. Low-frequency variants were aggregated for individual genes’ coding and regulatory regions. Association results in European ancestry samples were compared to single-marker association results in the same cohort. Gene-based associations were also combined in meta-analysis across individuals with European, Asian, African, and Latin American and Hispanic ancestry. Results In European ancestry samples, 14 genes were significantly associated (q FMNL3 (P = 6.11 × 10−6) and AC058822.1 (P = 1.47 × 10−4), represent new associations. High FMNL3 expression has previously been linked to poor prognosis in several other cancers. Meta-analysis of samples with diverse ancestry discovered further associations including established candidate genes ESR1 and CBLB. Furthermore, literature review and database query found further support for a biologically plausible link with cancer for genes CBLB, FMNL3, FGFR2, LSP1, MAP3K1, and SRGAP2C. Conclusions Using extended gene-based aggregation tests including coding and regulatory variation, we report identification of plausible target genes for previously identified single-marker associations with BC as well as the discovery of novel genes implicated in BC development. Including multi ancestral cohorts in this study enabled the identification of otherwise missed disease associations as ESR1 (P = 1.31 × 10−5), demonstrating the importance of diversifying study cohorts.

Published
2023
Full Text
View/download PDF

17. Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer

Author

Egeland, Eivind Valen, Boye, Kjetil, Park, Daehoon, Synnestvedt, Marit, Sauer, Torill, Naume, Bjørn, Borgen, Elin, Mælandsmo, Gunhild M., Sauer, Torill, Geisler, Jürgen, Hofvind, Solveig, Bathen, Tone F., Borgen, Elin, Børresen‐Dale, Anne‐Lise, Engebråten, Olav, Fodstad, Øystein, Garred, Øystein, Geitvik, Gry A., Kåresen, Rolf, Naume, Bjørn, Mælandsmo, Gunhild M., Russnes, Hege G., Schlichting, Ellen, Sørlie, Therese, Lingjærde, Ole C., Kristensen, Vessela N., Sahlberg, Kristine K., Skjerven, Helle K., Fritzman, Britt, and The Oslo Breast Cancer Consortium (OSBREAC)

Published
2017
Full Text
View/download PDF

23. LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer

Author

Sas‐Chen, Aldema, Aure, Miriam R, Leibovich, Limor, Carvalho, Silvia, Enuka, Yehoshua, Körner, Cindy, Polycarpou‐Schwarz, Maria, Lavi, Sara, Nevo, Nava, Kuznetsov, Yuri, Yuan, Justin, Azuaje, Francisco, Ulitsky, Igor, Diederichs, Sven, Wiemann, Stefan, Yakhini, Zohar, Kristensen, Vessela N, Børresen‐Dale, Anne‐Lise, Yarden, Yosef, Sauer, Torill, Geisler, Jürgen, Hofvind, Solveig, Bathen, Tone F, Borgen, Elin, Engebråten, Olav, Fodstad, Øystein, Garred, Øystein, Geitvik, Gry Aarum, Kåresen, Rolf, Naume, Bjørn, Mælandsmo, Gunhild Mari, Russnes, Hege G, Schlichting, Ellen, Sørlie, Therese, Lingjærde, Ole Christian, Sahlberg, Kristine Kleivi, Skjerven, Helle Kristine, and Fritzman, Britt

Published
2016
Full Text
View/download PDF

25. Common variants in breast cancer risk loci predispose to distinct tumor subtypes

Author

Ahearn, Thomas U., Zhang, Haoyu, Michailidou, Kyriaki, Milne, Roger L., Bolla, Manjeet K., Dennis, Joe, Dunning, Alison M., Lush, Michael, Wang, Qin, Andrulis, Irene L., Anton-Culver, Hoda, Arndt, Volker, Aronson, Kristan J., Auer, Paul L., Augustinsson, Annelie, Baten, Adinda, Becher, Heiko, Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Blomqvist, Carl, Bojesen, Stig E., Bonanni, Bernardo, Børresen-Dale, Anne Lise, Brauch, Hiltrud, Brenner, Hermann, Brooks-Wilson, Angela, Brüning, Thomas, Burwinkel, Barbara, Buys, Saundra S., Canzian, Federico, Castelao, Jose E., Chang-Claude, Jenny, Chanock, Stephen J., Chenevix-Trench, Georgia, Clarke, Christine L., Sahlberg, Kristine K., Ottestad, Lars, Kåresen, Rolf, Schlichting, Ellen, Holmen, Marit Muri, Sauer, Toril, Haakensen, Vilde, Engebråten, Olav, Naume, Bjørn, Fosså, Alexander, Kiserud, Cecile E., Reinertsen, Kristin V., Helland, Åslaug, Riis, Margit, Ahearn, Thomas U., Zhang, Haoyu, Michailidou, Kyriaki, Milne, Roger L., Bolla, Manjeet K., Dennis, Joe, Dunning, Alison M., Lush, Michael, Wang, Qin, Andrulis, Irene L., Anton-Culver, Hoda, Arndt, Volker, Aronson, Kristan J., Auer, Paul L., Augustinsson, Annelie, Baten, Adinda, Becher, Heiko, Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Blomqvist, Carl, Bojesen, Stig E., Bonanni, Bernardo, Børresen-Dale, Anne Lise, Brauch, Hiltrud, Brenner, Hermann, Brooks-Wilson, Angela, Brüning, Thomas, Burwinkel, Barbara, Buys, Saundra S., Canzian, Federico, Castelao, Jose E., Chang-Claude, Jenny, Chanock, Stephen J., Chenevix-Trench, Georgia, Clarke, Christine L., Sahlberg, Kristine K., Ottestad, Lars, Kåresen, Rolf, Schlichting, Ellen, Holmen, Marit Muri, Sauer, Toril, Haakensen, Vilde, Engebråten, Olav, Naume, Bjørn, Fosså, Alexander, Kiserud, Cecile E., Reinertsen, Kristin V., Helland, Åslaug, and Riis, Margit

Abstract

Background: Genome-wide association studies (GWAS) have identified multiple common breast cancer susceptibility variants. Many of these variants have differential associations by estrogen receptor (ER) status, but how these variants relate with other tumor features and intrinsic molecular subtypes is unclear. Methods: Among 106,571 invasive breast cancer cases and 95,762 controls of European ancestry with data on 173 breast cancer variants identified in previous GWAS, we used novel two-stage polytomous logistic regression models to evaluate variants in relation to multiple tumor features (ER, progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and grade) adjusting for each other, and to intrinsic-like subtypes. Results: Eighty-five of 173 variants were associated with at least one tumor feature (false discovery rate < 5%), most commonly ER and grade, followed by PR and HER2. Models for intrinsic-like subtypes found nearly all of these variants (83 of 85) associated at p < 0.05 with risk for at least one luminal-like subtype, and approximately half (41 of 85) of the variants were associated with risk of at least one non-luminal subtype, including 32 variants associated with triple-negative (TN) disease. Ten variants were associated with risk of all subtypes in different magnitude. Five variants were associated with risk of luminal A-like and TN subtypes in opposite directions. Conclusion: This report demonstrates a high level of complexity in the etiology heterogeneity of breast cancer susceptibility variants and can inform investigations of subtype-specific risk prediction.

Published
2022

28. Additional file 1 of Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015���2016

Author

Nilssen, Yngvar, Brustugun, Odd Terje, Eriksen, Morten Tandberg, Guren, Marianne G., Haug, Erik Skaaheim, Naume, Bj��rn, Schlichting, Ellen, and M��ller, Bj��rn

Abstract

Additional file 1: Supplementary Figure 1. The cumulative proportion per risk group of prostate cancer patients diagnosed in 2015-2016 in Norway by OF1, OF2, OF3 and OF4.

Published
2022
Full Text
View/download PDF

30. Abstract OT1-04-04: AXSANA - EUBREAST 3 (axillary surgery after neoadjuvant treatment): An international prospective multicenter cohort study of the EUBREAST study group to evaluate different surgical methods of axillary staging (sentinel lymph node biopsy, targeted axillary dissection, axillary dissection) in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy (NCT04373655)

Author

Kühn, Thorsten, primary, Hartmann, Steffi, additional, Stickeler, Elmar, additional, de Boniface, Jana, additional, Gentilini, Oreste, additional, Fröhlich, Sarah, additional, Ruf, Franziska, additional, Thill, Marc, additional, Hauptmann, Michael, additional, Cakmak, Guldeniz Karadeniz, additional, Rubio, Isabel, additional, Gasparri, Maria Luisa, additional, Kontos, Michaelis, additional, Bonci, Eduard-Alexandru, additional, Niinikoski, Laura, additional, Micco, Rosa Di, additional, Murawa, Dawid, additional, Pinto, David, additional, Peintinger, Florentia, additional, Solbach, Christine, additional, Appelgren, Matilda, additional, Blohmer, Jens-Uwe, additional, Weigel, Michael, additional, Kaltenecker, Gabriele, additional, Schrauder, Michael, additional, Simons, Janine, additional, Smidt, Marjolein, additional, Schlichting, Ellen, additional, Dostalek, Lukas, additional, Emelyanov, Alexander Sergeevich, additional, Thiemann, Elisabeth, additional, Gunay, Semra, additional, Loibl, Sybille, additional, and Banys-Paluchowski, Maggie, additional

Published
2022
Full Text
View/download PDF

34. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

Author

Johnson, Nichola, Maguire, Sarah, Morra, Anna, Kapoor, Pooja Middha, Tomczyk, Katarzyna, Jones, Michael E., Schoemaker, Minouk J., Gilham, Clare, Bolla, Manjeet K., Wang, Qin, Dennis, Joe, Ahearn, Thomas U., Andrulis, Irene L., Anton-Culver, Hoda, Antonenkova, Natalia N., Arndt, Volker, Aronson, Kristan J., Augustinsson, Annelie, Baynes, Caroline, Freeman, Laura E. Beane, Beckmann, Matthias W., Benitez, Javier, Bermisheva, Marina, Blomqvist, Carl, Boeckx, Bram, Bogdanova, Natalia V., Bojesen, Stig E., Brauch, Hiltrud, Brenner, Hermann, Burwinkel, Barbara, Campa, Daniele, Canzian, Federico, Castelao, Jose E., Chanock, Stephen J., Chenevix-Trench, Georgia, Clarke, Christine L., Conroy, Don M., Couch, Fergus J., Cox, Angela, Cross, Simon S., Czene, Kamila, Dörk, Thilo, Eliassen, A. Heather, Engel, Christoph, Evans, D. Gareth, Fasching, Peter A., Figueroa, Jonine, Floris, Giuseppe, Flyger, Henrik, Gago-Dominguez, Manuela, Gapstur, Susan M., García-Closas, Montserrat, Gaudet, Mia M., Giles, Graham G., Goldberg, Mark S., González-Neira, Anna, Guénel, Pascal, Hahnen, Eric, Haiman, Christopher A., Håkansson, Niclas, Hall, Per, Hamann, Ute, Harrington, Patricia A., Hart, Steven N., Hooning, Maartje J., Hopper, John L., Howell, Anthony, Hunter, David J., Jager, Agnes, Jakubowska, Anna, John, Esther M., Kaaks, Rudolf, Keeman, Renske, Khusnutdinova, Elza, Kitahara, Cari M., Kosma, Veli-Matti, Koutros, Stella, Kraft, Peter, Kristensen, Vessela N., Kurian, Allison W., Lambrechts, Diether, Le Marchand, Loic, Linet, Martha, Lubiński, Jan, Mannermaa, Arto, Manoukian, Siranoush, Margolin, Sara, Martens, John W. M., Mavroudis, Dimitrios, Mayes, Rebecca, Meindl, Alfons, Milne, Roger L., Neuhausen, Susan L., Nevanlinna, Heli, Newman, William G., Nielsen, Sune F., Nordestgaard, Børge G., Obi, Nadia, Olshan, Andrew F., Olson, Janet E., Olsson, Håkan, Orban, Ester, Park-Simon, Tjoung-Won, Peterlongo, Paolo, Plaseska-Karanfilska, Dijana, Pylkäs, Katri, Rennert, Gad, Rennert, Hedy S., Ruddy, Kathryn J., Saloustros, Emmanouil, Sandler, Dale P., Sawyer, Elinor J., Schmutzler, Rita K., Scott, Christopher, Shu, Xiao-Ou, Simard, Jacques, Smichkoska, Snezhana, Sohn, Christof, Southey, Melissa C., Spinelli, John J., Stone, Jennifer, Tamimi, Rulla M., Taylor, Jack A., Tollenaar, Rob A. E. M., Tomlinson, Ian, Troester, Melissa A., Truong, Thérèse, Vachon, Celine M., van Veen, Elke M., Wang, Sophia S., Weinberg, Clarice R., Wendt, Camilla, Wildiers, Hans, Winqvist, Robert, Wolk, Alicja, Zheng, Wei, Ziogas, Argyrios, Dunning, Alison M., Pharoah, Paul D. P., Easton, Douglas F., Howie, A. Forbes, Peto, Julian, dos-Santos-Silva, Isabel, Swerdlow, Anthony J., Chang-Claude, Jenny, Schmidt, Marjanka K., Orr, Nick, Fletcher, Olivia, Børresen-Dale, Anne-Lise, Alnæs, Grethe I. Grenaker, Sahlberg, Kristine K., Ottestad, Lars, Kåresen, Rolf, Schlichting, Ellen, Holmen, Marit Muri, Sauer, Toril, Haakensen, Vilde, Engebråten, Olav, Naume, Bjørn, Fosså, Alexander, Kiserud, Cecile E., Reinertsen, Kristin V., Helland, Åslaug, Riis, Margit, Geisler, Jürgen, Bowtell, David D. L., deFazio, Anna, Webb, Penelope M., Clarke, Christine, Marsh, Deborah, Scott, Rodney, Baxter, Robert, Yip, Desmond, Carpenter, Jane, Davis, Alison, Pathmanathan, Nirmala, Simpson, Peter, Graham, Dinny, Sachchithananthan, Mythily, Amor, David, Andrews, Lesley, Antill, Yoland, Balleine, Rosemary, Beesley, Jonathan, Bennett, Ian, Bogwitz, Michael, Botes, Leon, Brennan, Meagan, Brown, Melissa, Buckley, Michael, Burke, Jo, Butow, Phyllis, Caldon, Liz, Campbell, Ian, Chauhan, Deepa, Chauhan, Manisha, Christian, Alice, Cohen, Paul, Colley, Alison, Crook, Ashley, Cui, James, Cummings, Margaret, Dawson, Sarah-Jane, DeFazio, Anna, Delatycki, Martin, Dickson, Rebecca, Dixon, Joanne, Edkins, Ted, Edwards, Stacey, Farshid, Gelareh, Fellows, Andrew, Fenton, Georgina, Field, Michael, Flanagan, James, Fong, Peter, Forrest, Laura, Fox, Stephen, French, Juliet, Friedlander, Michael, Gaff, Clara, Gattas, Mike, George, Peter, Greening, Sian, Harris, Marion, Hart, Stewart, Hayward, Nick, Hopper, John, Hoskins, Cass, Hunt, Clare, James, Paul, Jenkins, Mark, Kidd, Alexa, Kirk, Judy, Koehler, Jessica, Kollias, James, Lakhani, Sunil, Lawrence, Mitchell, Lindeman, Geoff, Lipton, Lara, Lobb, Liz, Mann, Graham, McLachlan, Sue Anne, Meiser, Bettina, Milne, Roger, Nightingale, Sophie, O’Connell, Shona, O’Sullivan, Sarah, Ortega, David Gallego, Pachter, Nick, Patterson, Briony, Pearn, Amy, Phillips, Kelly, Pieper, Ellen, Rickard, Edwina, Robinson, Bridget, Saleh, Mona, Salisbury, Elizabeth, Saunders, Christobel, Saunus, Jodi, Scott, Clare, Sexton, Adrienne, Shelling, Andrew, Southey, Melissa, Spurdle, Amanda, Taylor, Jessica, Taylor, Renea, Thorne, Heather, Trainer, Alison, Tucker, Kathy, Visvader, Jane, Walker, Logan, Williams, Rachael, Winship, Ingrid, Young, Mary Ann, Johnson, Nichola [0000-0002-8230-5662], Kapoor, Pooja Middha [0000-0001-5503-8215], Dennis, Joe [0000-0003-4591-1214], Brenner, Hermann [0000-0002-6129-1572], Canzian, Federico [0000-0002-4261-4583], Cox, Angela [0000-0002-5138-1099], Fasching, Peter A. [0000-0003-4885-8471], Hart, Steven N. [0000-0001-7714-2734], Jakubowska, Anna [0000-0002-5650-0501], Kurian, Allison W. [0000-0002-6175-9470], Peterlongo, Paolo [0000-0001-6951-6855], Sawyer, Elinor J. [0000-0001-8285-4111], Tomlinson, Ian [0000-0003-3037-1470], Truong, Thérèse [0000-0002-2943-6786], Pharoah, Paul D. P. [0000-0001-8494-732X], Peto, Julian [0000-0002-1685-8912], Apollo - University of Cambridge Repository, Medical Oncology, HUS Comprehensive Cancer Center, Department of Oncology, Clinicum, Helsinki University Hospital Area, University of Helsinki, HUS Gynecology and Obstetrics, Department of Obstetrics and Gynecology, Fasching, Peter A [0000-0003-4885-8471], Hart, Steven N [0000-0001-7714-2734], Kurian, Allison W [0000-0002-6175-9470], Sawyer, Elinor J [0000-0001-8285-4111], and Pharoah, Paul DP [0000-0001-8494-732X]

Subjects
Cancer Research, CYP3A5, Physiology, Genome-wide association study, Breast cancer, 0302 clinical medicine, Epidemiology, Receptors, IMPUTATION, Medicine, Cytochrome P-450 CYP3A, Cancer genetics, Progesterone, 0303 health sciences, article, 1112 Oncology and Carcinogenesis, 1117 Public Health and Health Services, AOCS Group, Single Nucleotide, humanities, 3. Good health, Receptors, Estrogen, Oncology, Hormone receptor, 030220 oncology & carcinogenesis, kConFab Investigators, Pregnanediol, Female, Receptors, Progesterone, Medical Genetics, medicine.medical_specialty, Estrone, Urinary system, 3122 Cancers, ABCTB Investigators, 631/67/2324, Breast Neoplasms, Polymorphism, Single Nucleotide, NBCS Collaborators, 03 medical and health sciences, Cancer epidemiology, SDG 3 - Good Health and Well-being, 631/67/68, Humans, Oncology & Carcinogenesis, Allele, GENOME-WIDE ASSOCIATION, Polymorphism, CYP3A7, Alleles, 030304 developmental biology, Medicinsk genetik, business.industry, 631/67/1347, medicine.disease, Case-Control Studies, Genome-Wide Association Study, Premenopause, Estrogen, business, Hormone
Abstract

Background Epidemiological studies provide strong evidence for a role of endogenous sex hormones in the aetiology of breast cancer. The aim of this analysis was to identify genetic variants that are associated with urinary sex-hormone levels and breast cancer risk. Methods We carried out a genome-wide association study of urinary oestrone-3-glucuronide and pregnanediol-3-glucuronide levels in 560 premenopausal women, with additional analysis of progesterone levels in 298 premenopausal women. To test for the association with breast cancer risk, we carried out follow-up genotyping in 90,916 cases and 89,893 controls from the Breast Cancer Association Consortium. All women were of European ancestry. Results For pregnanediol-3-glucuronide, there were no genome-wide significant associations; for oestrone-3-glucuronide, we identified a single peak mapping to the CYP3A locus, annotated by rs45446698. The minor rs45446698-C allele was associated with lower oestrone-3-glucuronide (−49.2%, 95% CI −56.1% to −41.1%, P = 3.1 × 10–18); in follow-up analyses, rs45446698-C was also associated with lower progesterone (−26.7%, 95% CI −39.4% to −11.6%, P = 0.001) and reduced risk of oestrogen and progesterone receptor-positive breast cancer (OR = 0.86, 95% CI 0.82–0.91, P = 6.9 × 10–8). Conclusions The CYP3A7*1C allele is associated with reduced risk of hormone receptor-positive breast cancer possibly mediated via an effect on the metabolism of endogenous sex hormones in premenopausal women.

Published
2021

35. Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study

Author

Banys-Paluchowski, Maggie Gasparri, Maria Luisa de Boniface, Jana Gentilini, Oreste Stickeler, Elmar Hartmann, Steffi and Thill, Marc Rubio, Isabel T. Di Micco, Rosa Bonci, Eduard-Alexandru Niinikoski, Laura Kontos, Michalis and Karadeniz Cakmak, Guldeniz Hauptmann, Michael Peintinger, Florentia Pinto, David Matrai, Zoltan Murawa, Dawid and Kadayaprath, Geeta Dostalek, Lukas Nina, Helidon Krivorotko, Petr Classe, Jean-Marc Schlichting, Ellen Appelgren, Matilda and Paluchowski, Peter Solbach, Christine Blohmer, Jens-Uwe and Kuehn, Thorsten AXSANA Study Grp

Abstract

Simple Summary Currently, it is unclear which kind of axillary staging surgery breast cancer patients with lymph node metastasis should receive after neoadjuvant chemotherapy. For decades, these patients have been treated with a full axillary lymph node dissection, even if they converted to clinical node negativity. However, the removal of a large number of lymph nodes during the procedure can increase arm morbidity and impact quality of life. Therefore, several studies investigated less radical surgical strategies in this setting, such as sentinel lymph node biopsy or targeted axillary dissection, i.e., removal of a previously marked node combined with sentinel node removal. In this review, we summarize current evidence on the different surgical techniques and compare national and international recommendations. We show that many questions regarding oncological safety of different surgery types and the optimal marking technique remain unanswered and present the multinational prospective cohort study AXSANA that will address these open issues. In the last two decades, surgical methods for axillary staging in breast cancer patients have become less extensive, and full axillary lymph node dissection (ALND) is confined to selected patients. In initially node-positive patients undergoing neoadjuvant chemotherapy, however, the optimal management remains unclear. Current guidelines vary widely, endorsing different strategies. We performed a literature review on axillary staging strategies and their place in international recommendations. This overview defines knowledge gaps associated with specific procedures, summarizes currently ongoing clinical trials that address these unsolved issues, and provides the rationale for further research. While some guidelines have already implemented surgical de-escalation, replacing ALND with, e.g., sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD) in cN+ patients converting to clinical node negativity, others recommend ALND. Numerous techniques are in use for tagging lymph node metastasis, but many questions regarding the marking technique, i.e., the optimal time for marker placement and the number of marked nodes, remain unanswered. The optimal number of SLNs to be excised also remains a matter of debate. Data on oncological safety and quality of life following different staging procedures are lacking. These results provide the rationale for the multinational prospective cohort study AXSANA initiated by EUBREAST, which started enrollment in June 2020 and aims at recruiting 3000 patients in 20 countries (NCT04373655; Funded by AGO-B, Claudia von Schilling Foundation for Breast Cancer Research, AWOgyn, EndoMag, Mammotome, and MeritMedical).

Published
2021

36. Surgical management of the axilla in clinically node-positive breast cancer patients converting to clinical node negativity through neoadjuvant chemotherapy: current status, knowledge gaps, and rationale for the EUBREAST-03 AXSANA study

Author

AXSANA Study Group, Banys-Paluchowski, Maggie, Gasparri, Maria Luisa, de Boniface, Jana, Gentilini, Oreste, Stickeler, Elmar, Hartmann, Steffi, Thill, Marc, Rubio, Isabel T., Di Micco, Rosa, Bonci, Eduard-Alexandru, Niinikoski, Laura, Kontos, Michalis, Cakmak, Guldeniz Karadeniz, Hauptmann, Michael, Peintinger, Florentia, Pinto, David, Matrai, Zoltan, Murawa, Dawid, Kadayaprath, Geeta, Dostalek, Lukas, Nina, Helidon, Krivorotko, Petr, Classe, Jean-Marc, Schlichting, Ellen, Appelgren, Matilda, Paluchowski, Peter, Solbach, Christine, Blohmer, Jens-Uwe, Kühn, Thorsten, AXSANA Study Group, Banys-Paluchowski, Maggie, Gasparri, Maria Luisa, de Boniface, Jana, Gentilini, Oreste, Stickeler, Elmar, Hartmann, Steffi, Thill, Marc, Rubio, Isabel T., Di Micco, Rosa, Bonci, Eduard-Alexandru, Niinikoski, Laura, Kontos, Michalis, Cakmak, Guldeniz Karadeniz, Hauptmann, Michael, Peintinger, Florentia, Pinto, David, Matrai, Zoltan, Murawa, Dawid, Kadayaprath, Geeta, Dostalek, Lukas, Nina, Helidon, Krivorotko, Petr, Classe, Jean-Marc, Schlichting, Ellen, Appelgren, Matilda, Paluchowski, Peter, Solbach, Christine, Blohmer, Jens-Uwe, and Kühn, Thorsten

Abstract

Simple Summary: Currently, it is unclear which kind of axillary staging surgery breast cancer patients with lymph node metastasis should receive after neoadjuvant chemotherapy. For decades, these patients have been treated with a full axillary lymph node dissection, even if they converted to clinical node negativity. However, the removal of a large number of lymph nodes during the procedure can increase arm morbidity and impact quality of life. Therefore, several studies investigated less radical surgical strategies in this setting, such as sentinel lymph node biopsy or targeted axillary dissection, i.e., removal of a previously marked node combined with sentinel node removal. In this review, we summarize current evidence on the different surgical techniques and compare national and international recommendations. We show that many questions regarding oncological safety of different surgery types and the optimal marking technique remain unanswered and present the multinational prospective cohort study AXSANA that will address these open issues. Abstract: In the last two decades, surgical methods for axillary staging in breast cancer patients have become less extensive, and full axillary lymph node dissection (ALND) is confined to selected patients. In initially node-positive patients undergoing neoadjuvant chemotherapy, however, the optimal management remains unclear. Current guidelines vary widely, endorsing different strategies. We performed a literature review on axillary staging strategies and their place in international recommendations. This overview defines knowledge gaps associated with specific procedures, summarizes currently ongoing clinical trials that address these unsolved issues, and provides the rationale for further research. While some guidelines have already implemented surgical de-escalation, replacing ALND with, e.g., sentinel lymph node biopsy (SLNB) or targeted axillary dissection (TAD) in cN+ patients converting to clinical node negativity, ot

Published
2021

37. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

Author

Morra, Anna, Escala-Garcia, Maria, Beesley, Jonathan, Keeman, Renske, Canisius, Sander, Ahearn, Thomas U., Andrulis, Irene L., Anton-Culver, Hoda, Arndt, Volker, Auer, Paul L., Augustinsson, Annelie, Beane Freeman, Laura E., Becher, Heiko, Beckmann, Matthias W., Behrens, Sabine, Bojesen, Stig E., Bolla, Manjeet K., Brenner, Hermann, Brüning, Thomas, Buys, Saundra S., Caan, Bette, Campa, Daniele, Canzian, Federico, Castelao, Jose E., Chang-Claude, Jenny, Chanock, Stephen J., Cheng, Ting Yuan David, Clarke, Christine L., Børresen-Dale, Anne Lise, Sahlberg, Kristine K., Ottestad, Lars, Kåresen, Rolf, Schlichting, Ellen, Holmen, Marit Muri, Sauer, Toril, Haakensen, Vilde, Engebråten, Olav, Naume, Bjørn, Fosså, Alexander, Kiserud, Cecile E., Reinertsen, Kristin V., Helland, Åslaug, Riis, Margit, Geisler, Jürgen, Grenaker Alnæs, Grethe I., Colonna, Sarah V., Hooning, Maartje J., Jager, Agnes, Kraft, Peter, Martens, John W.M., Morra, Anna, Escala-Garcia, Maria, Beesley, Jonathan, Keeman, Renske, Canisius, Sander, Ahearn, Thomas U., Andrulis, Irene L., Anton-Culver, Hoda, Arndt, Volker, Auer, Paul L., Augustinsson, Annelie, Beane Freeman, Laura E., Becher, Heiko, Beckmann, Matthias W., Behrens, Sabine, Bojesen, Stig E., Bolla, Manjeet K., Brenner, Hermann, Brüning, Thomas, Buys, Saundra S., Caan, Bette, Campa, Daniele, Canzian, Federico, Castelao, Jose E., Chang-Claude, Jenny, Chanock, Stephen J., Cheng, Ting Yuan David, Clarke, Christine L., Børresen-Dale, Anne Lise, Sahlberg, Kristine K., Ottestad, Lars, Kåresen, Rolf, Schlichting, Ellen, Holmen, Marit Muri, Sauer, Toril, Haakensen, Vilde, Engebråten, Olav, Naume, Bjørn, Fosså, Alexander, Kiserud, Cecile E., Reinertsen, Kristin V., Helland, Åslaug, Riis, Margit, Geisler, Jürgen, Grenaker Alnæs, Grethe I., Colonna, Sarah V., Hooning, Maartje J., Jager, Agnes, Kraft, Peter, and Martens, John W.M.

Abstract

Background: Given the high heterogeneity among breast tumors, associations between common germline genetic variants and survival that may exist within specific subgroups could go undetected in an unstratified set of breast cancer patients. Methods: We performed genome-wide association analyses within 15 subgroups of breast cancer patients based on prognostic factors, including hormone receptors, tumor grade, age, and type of systemic treatment. Analyses were based on 91,686 female patients of European ancestry from the Breast Cancer Association Consortium, including 7531 breast cancer-specific deaths over a median follow-up of 8.1 years. Cox regression was used to assess associations of common germline variants with 15-year and 5-year breast cancer-specific survival. We assessed the probability of these associations being true positives via the Bayesian false discovery probability (BFDP < 0.15). Results: Evidence of associations with breast cancer-specific survival was observed in three patient subgroups, with variant rs5934618 in patients with grade 3 tumors (15-year-hazard ratio (HR) [95% confidence interval (CI)] 1.32 [1.20, 1.45], P = 1.4E−08, BFDP = 0.01, per G allele); variant rs4679741 in patients with ER-positive tumors treated with endocrine therapy (15-year-HR [95% CI] 1.18 [1.11, 1.26], P = 1.6E−07, BFDP = 0.09, per G allele); variants rs1106333 (15-year-HR [95% CI] 1.68 [1.39,2.03], P = 5.6E−08, BFDP = 0.12, per A allele) and rs78754389 (5-year-HR [95% CI] 1.79 [1.46,2.20], P = 1.7E−08, BFDP = 0.07, per A allele), in patients with ER-negative tumors treated with chemotherapy. Conclusions: We found evidence of four loci associated with breast cancer-specific survival within three patient subgroups. There was limited evidence for the existence of associations in other patient subgroups. However, the power for many subgroups is limited due to the low number of events. Even so, our results suggest that the impact of common germline genetic variants on

Published
2021

38. CYP3A7*1C allele:linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

Author

Johnson, Nichola, Maguire, Sarah, Morra, Anna, Kapoor, Pooja Middha, Tomczyk, Katarzyna, Jones, Michael E., Schoemaker, Minouk J., Gilham, Clare, Bolla, Manjeet K., Wang, Qin, Dennis, Joe, Ahearn, Thomas U., Andrulis, Irene L., Anton-Culver, Hoda, Antonenkova, Natalia N., Arndt, Volker, Aronson, Kristan J., Augustinsson, Annelie, Baynes, Caroline, Freeman, Laura E.Beane, Beckmann, Matthias W., Benitez, Javier, Bermisheva, Marina, Blomqvist, Carl, Boeckx, Bram, Bogdanova, Natalia V., Bojesen, Stig E., Brauch, Hiltrud, Brenner, Hermann, Burwinkel, Barbara, Campa, Daniele, Canzian, Federico, Castelao, Jose E., Chanock, Stephen J., Chenevix-Trench, Georgia, Clarke, Christine L., Børresen-Dale, Anne Lise, Alnæs, Grethe I.Grenaker, Sahlberg, Kristine K., Ottestad, Lars, Kåresen, Rolf, Schlichting, Ellen, Holmen, Marit Muri, Sauer, Toril, Haakensen, Vilde, Riis, Margit, Flyger, Henrik, Nielsen, Sune F., Nordestgaard, Børge G., Scott, Christopher, Johnson, Nichola, Maguire, Sarah, Morra, Anna, Kapoor, Pooja Middha, Tomczyk, Katarzyna, Jones, Michael E., Schoemaker, Minouk J., Gilham, Clare, Bolla, Manjeet K., Wang, Qin, Dennis, Joe, Ahearn, Thomas U., Andrulis, Irene L., Anton-Culver, Hoda, Antonenkova, Natalia N., Arndt, Volker, Aronson, Kristan J., Augustinsson, Annelie, Baynes, Caroline, Freeman, Laura E.Beane, Beckmann, Matthias W., Benitez, Javier, Bermisheva, Marina, Blomqvist, Carl, Boeckx, Bram, Bogdanova, Natalia V., Bojesen, Stig E., Brauch, Hiltrud, Brenner, Hermann, Burwinkel, Barbara, Campa, Daniele, Canzian, Federico, Castelao, Jose E., Chanock, Stephen J., Chenevix-Trench, Georgia, Clarke, Christine L., Børresen-Dale, Anne Lise, Alnæs, Grethe I.Grenaker, Sahlberg, Kristine K., Ottestad, Lars, Kåresen, Rolf, Schlichting, Ellen, Holmen, Marit Muri, Sauer, Toril, Haakensen, Vilde, Riis, Margit, Flyger, Henrik, Nielsen, Sune F., Nordestgaard, Børge G., and Scott, Christopher

Abstract

Background: Epidemiological studies provide strong evidence for a role of endogenous sex hormones in the aetiology of breast cancer. The aim of this analysis was to identify genetic variants that are associated with urinary sex-hormone levels and breast cancer risk. Methods: We carried out a genome-wide association study of urinary oestrone-3-glucuronide and pregnanediol-3-glucuronide levels in 560 premenopausal women, with additional analysis of progesterone levels in 298 premenopausal women. To test for the association with breast cancer risk, we carried out follow-up genotyping in 90,916 cases and 89,893 controls from the Breast Cancer Association Consortium. All women were of European ancestry. Results: For pregnanediol-3-glucuronide, there were no genome-wide significant associations; for oestrone-3-glucuronide, we identified a single peak mapping to the CYP3A locus, annotated by rs45446698. The minor rs45446698-C allele was associated with lower oestrone-3-glucuronide (−49.2%, 95% CI −56.1% to −41.1%, P = 3.1 × 10–18); in follow-up analyses, rs45446698-C was also associated with lower progesterone (−26.7%, 95% CI −39.4% to −11.6%, P = 0.001) and reduced risk of oestrogen and progesterone receptor-positive breast cancer (OR = 0.86, 95% CI 0.82–0.91, P = 6.9 × 10–8). Conclusions: The CYP3A7*1C allele is associated with reduced risk of hormone receptor-positive breast cancer possibly mediated via an effect on the metabolism of endogenous sex hormones in premenopausal women.

Published
2021

39. Mendelian randomisation study of smoking exposure in relation to breast cancer risk

Author

Park, Hanla A., Neumeyer, Sonja, Michailidou, Kyriaki, Bolla, Manjeet K., Wang, Qin, Dennis, Joe, Ahearn, Thomas U., Andrulis, Irene L., Anton-Culver, Hoda, Antonenkova, Natalia N., Arndt, Volker, Aronson, Kristan J., Augustinsson, Annelie, Baten, Adinda, Beane Freeman, Laura E., Becher, Heiko, Beckmann, Matthias W., Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Bogdanova, Natalia V., Bojesen, Stig E., Brauch, Hiltrud, Brenner, Hermann, Brucker, Sara Y., Burwinkel, Barbara, Campa, Daniele, Canzian, Federico, Castelao, Jose E., Chanock, Stephen J., Chenevix-Trench, Georgia, Clarke, Christine L., Børresen-Dale, Anne Lise, Grenaker Alnæs, Grethe I., Sahlberg, Kristine K., Ottestad, Lars, Kåresen, Rolf, Schlichting, Ellen, Holmen, Marit Muri, Sauer, Toril, Haakensen, Vilde, Engebråten, Olav, Naume, Bjørn, Fosså, Alexander, Kiserud, Cecile E., Reinertsen, Kristin V., Riis, Margit, Flyger, Henrik, Nordestgaard, Børge G., Scott, Christopher, Park, Hanla A., Neumeyer, Sonja, Michailidou, Kyriaki, Bolla, Manjeet K., Wang, Qin, Dennis, Joe, Ahearn, Thomas U., Andrulis, Irene L., Anton-Culver, Hoda, Antonenkova, Natalia N., Arndt, Volker, Aronson, Kristan J., Augustinsson, Annelie, Baten, Adinda, Beane Freeman, Laura E., Becher, Heiko, Beckmann, Matthias W., Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Bogdanova, Natalia V., Bojesen, Stig E., Brauch, Hiltrud, Brenner, Hermann, Brucker, Sara Y., Burwinkel, Barbara, Campa, Daniele, Canzian, Federico, Castelao, Jose E., Chanock, Stephen J., Chenevix-Trench, Georgia, Clarke, Christine L., Børresen-Dale, Anne Lise, Grenaker Alnæs, Grethe I., Sahlberg, Kristine K., Ottestad, Lars, Kåresen, Rolf, Schlichting, Ellen, Holmen, Marit Muri, Sauer, Toril, Haakensen, Vilde, Engebråten, Olav, Naume, Bjørn, Fosså, Alexander, Kiserud, Cecile E., Reinertsen, Kristin V., Riis, Margit, Flyger, Henrik, Nordestgaard, Børge G., and Scott, Christopher

Abstract

Background: Despite a modest association between tobacco smoking and breast cancer risk reported by recent epidemiological studies, it is still equivocal whether smoking is causally related to breast cancer risk. Methods: We applied Mendelian randomisation (MR) to evaluate a potential causal effect of cigarette smoking on breast cancer risk. Both individual-level data as well as summary statistics for 164 single-nucleotide polymorphisms (SNPs) reported in genome-wide association studies of lifetime smoking index (LSI) or cigarette per day (CPD) were used to obtain MR effect estimates. Data from 108,420 invasive breast cancer cases and 87,681 controls were used for the LSI analysis and for the CPD analysis conducted among ever-smokers from 26,147 cancer cases and 26,072 controls. Sensitivity analyses were conducted to address pleiotropy. Results: Genetically predicted LSI was associated with increased breast cancer risk (OR 1.18 per SD, 95% CI: 1.07–1.30, P = 0.11 × 10–2), but there was no evidence of association for genetically predicted CPD (OR 1.02, 95% CI: 0.78–1.19, P = 0.85). The sensitivity analyses yielded similar results and showed no strong evidence of pleiotropic effect. Conclusion: Our MR study provides supportive evidence for a potential causal association with breast cancer risk for lifetime smoking exposure but not cigarettes per day among smokers.

Published
2021

41. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk

Author

Liu, Jingjing, Prager - van der Smissen, Wendy J. C., Collée, J. Margriet, Bolla, Manjeet K., Wang, Qin, Michailidou, Kyriaki, Dennis, Joe, Ahearn, Thomas U., Aittomäki, Kristiina, Ambrosone, Christine B., Andrulis, Irene L., Anton-Culver, Hoda, Antonenkova, Natalia N., Arndt, Volker, Arnold, Norbert, Aronson, Kristan J., Augustinsson, Annelie, Auvinen, Päivi, Becher, Heiko, Beckmann, Matthias W., Behrens, Sabine, Bermisheva, Marina, Bernstein, Leslie, Bogdanova, Natalia V., Bogdanova-Markov, Nadja, Bojesen, Stig E., Brauch, Hiltrud, Brenner, Hermann, Briceno, Ignacio, Brucker, Sara Y., Brüning, Thomas, Burwinkel, Barbara, Cai, Qiuyin, Cai, Hui, Campa, Daniele, Canzian, Federico, Castelao, Jose E., Chang-Claude, Jenny, Chanock, Stephen J., Choi, Ji-Yeob, Christiaens, Melissa, Clarke, Christine L., Couch, Fergus J., Czene, Kamila, Daly, Mary B., Devilee, Peter, dos-Santos-Silva, Isabel, Dwek, Miriam, Eccles, Diana M., Eliassen, A. Heather, Fasching, Peter A., Figueroa, Jonine, Flyger, Henrik, Fritschi, Lin, Gago-Dominguez, Manuela, Gapstur, Susan M., García-Closas, Montserrat, García-Sáenz, José A., Gaudet, Mia M., Giles, Graham G., Goldberg, Mark S., Goldgar, David E., Guénel, Pascal, Haiman, Christopher A., Håkansson, Niclas, Hall, Per, Harrington, Patricia A., Hart, Steven N., Hartman, Mikael, Hillemanns, Peter, Hopper, John L., Hou, Ming-Feng, Hunter, David J., Huo, Dezheng, Ito, Hidemi, Iwasaki, Motoki, Jakimovska, Milena, Jakubowska, Anna, John, Esther M., Kaaks, Rudolf, Kang, Daehee, Keeman, Renske, Khusnutdinova, Elza, Kim, Sung-Won, Kraft, Peter, Kristensen, Vessela N., Kurian, Allison W., Le Marchand, Loic, Li, Jingmei, Lindblom, Annika, Lophatananon, Artitaya, Luben, Robert N., Lubiński, Jan, Mannermaa, Arto, Manoochehri, Mehdi, Manoukian, Siranoush, Margolin, Sara, Mariapun, Shivaani, Matsuo, Keitaro, Maurer, Tabea, Mavroudis, Dimitrios, Meindl, Alfons, Menon, Usha, Milne, Roger L., Muir, Kenneth, Mulligan, Anna Marie, Neuhausen, Susan L., Nevanlinna, Heli, Offit, Kenneth, Olopade, Olufunmilayo I., Olson, Janet E., Olsson, Håkan, Orr, Nick, Park, Sue K., Peterlongo, Paolo, Peto, Julian, Plaseska-Karanfilska, Dijana, Presneau, Nadege, Rack, Brigitte, Rau-Murthy, Rohini, Rennert, Gad, Rennert, Hedy S., Rhenius, Valerie, Romero, Atocha, Ruebner, Matthias, Saloustros, Emmanouil, Schmutzler, Rita K., Schneeweiss, Andreas, Scott, Christopher, Shah, Mitul, Shen, Chen-Yang, Shu, Xiao-Ou, Simard, Jacques, Sohn, Christof, Southey, Melissa C., Spinelli, John J., Tamimi, Rulla M., Tapper, William J., Teo, Soo H., Terry, Mary Beth, Torres, Diana, Truong, Thérèse, Untch, Michael, Vachon, Celine M., van Asperen, Christi J., Wolk, Alicja, Yamaji, Taiki, Zheng, Wei, Ziogas, Argyrios, Ziv, Elad, Torres-Mejía, Gabriela, Dörk, Thilo, Swerdlow, Anthony J., Hamann, Ute, Schmidt, Marjanka K., Dunning, Alison M., Pharoah, Paul D. P., Easton, Douglas F., Hooning, Maartje J., Martens, John W. M., Hollestelle, Antoinette, Sahlberg, Kristine K., Børresen-Dale, Anne-Lise, Ottestad, Lars, Kåresen, Rolf, Schlichting, Ellen, Holmen, Marit Muri, Sauer, Toril, Haakensen, Vilde, Engebråten, Olav, Naume, Bjørn, Fosså, Alexander, Kiserud, Cecile E., Reinertsen, Kristin V., Helland, Åslaug, Riis, Margit, Geisler, Jürgen, Alnæs, Grethe I. Grenaker, Bathen, Tone F., Borgen, Elin, Fritzman, Britt, Garred, Øystein, Geitvik, Gry Aarum, Hofvind, Solveig, Langerød, Anita, Lingjærde, Ole Christian, Mælandsmo, Gunhild Mari, Russnes, Hege G, Skjerven, Helle Kristine, Sørlie, Therese, Clarke, Christine, Marsh, Deborah, Scott, Rodney, Baxter, Robert, Yip, Desmond, Carpenter, Jane, Davis, Alison, Pathmanathan, Nirmala, Simpson, Peter, Graham, Dinny, Sachchithananthan, Mythily, and Apollo - University of Cambridge Repository

Subjects
631/67, 631/208, article, skin and connective tissue diseases, 692/499, 692/4028
Abstract

In breast cancer, high levels of homeobox protein Hox-B13 (HOXB13) have been associated with disease progression of ER-positive breast cancer patients and resistance to tamoxifen treatment. Since HOXB13 p.G84E is a prostate cancer risk allele, we evaluated the association between HOXB13 germline mutations and breast cancer risk in a previous study consisting of 3,270 familial non-BRCA1/2 breast cancer cases and 2,327 controls from the Netherlands. Although both recurrent HOXB13 mutations p.G84E and p.R217C were not associated with breast cancer risk, the risk estimation for p.R217C was not very precise. To provide more conclusive evidence regarding the role of HOXB13 in breast cancer susceptibility, we here evaluated the association between HOXB13 mutations and increased breast cancer risk within 81 studies of the international Breast Cancer Association Consortium containing 68,521 invasive breast cancer patients and 54,865 controls. Both HOXB13 p.G84E and p.R217C did not associate with the development of breast cancer in European women, neither in the overall analysis (OR = 1.035, 95% CI = 0.859–1.246, P = 0.718 and OR = 0.798, 95% CI = 0.482–1.322, P = 0.381 respectively), nor in specific high-risk subgroups or breast cancer subtypes. Thus, although involved in breast cancer progression, HOXB13 is not a material breast cancer susceptibility gene.

Published
2020

42. Axillary Staging in the Setting of a Preoperative Diagnosis of Ductal Cancer In Situ (DCIS) : Results of an International Expert Panel and a Critical Guideline Performance Using Frequentist and Bayesian Analysis

Author

Karakatsanis, Andreas, Foukakis, Theodoros, Karlsson, Per, Mamounas, Eleftherios, Chagpar, Anees, Boyages, John, Rubio, Isabel, Naume, Bjørn, Mauri, Davide, van der Wall, Elsken, Shah, Chirag, Kwong, Ava, McAuliffe, Priscilla, Gentilini, Oreste, Ignatiadis, Michail, Schlichting, Ellen, Zgajnar, Janez, Meani, Francesco, Tasoulis, Marios Konstantinos, Whitworth, Pat, Weber, Walter, Charalampoudis, Petros, Gulluoglu, Bahadir, Pistioli, Lida, Tvedskov, Tove Filtenborg, Leidenius, Marjut, Mann, Bruce, Witkamp, Arjen, Wyld, Lynda, di Micco, Rosa, Markopoulos, Christos, Valachis, Antonis, Wärnberg, Fredrik, Karakatsanis, Andreas, Foukakis, Theodoros, Karlsson, Per, Mamounas, Eleftherios, Chagpar, Anees, Boyages, John, Rubio, Isabel, Naume, Bjørn, Mauri, Davide, van der Wall, Elsken, Shah, Chirag, Kwong, Ava, McAuliffe, Priscilla, Gentilini, Oreste, Ignatiadis, Michail, Schlichting, Ellen, Zgajnar, Janez, Meani, Francesco, Tasoulis, Marios Konstantinos, Whitworth, Pat, Weber, Walter, Charalampoudis, Petros, Gulluoglu, Bahadir, Pistioli, Lida, Tvedskov, Tove Filtenborg, Leidenius, Marjut, Mann, Bruce, Witkamp, Arjen, Wyld, Lynda, di Micco, Rosa, Markopoulos, Christos, Valachis, Antonis, and Wärnberg, Fredrik

Abstract

Background/Objective: Sentinel lymph node biopsy (SLNB) is not routine in DCIS. Guidelines suggest SLNB when there is high risk for underlying invasion (large size, high grade, symptomatic lesion) or for detection failure (e.g., after mastectomy). However, guidelines and current practice patterns are inconsistent. Moreover, whilst SLNB is thought to be feasible and accurate after wide local excision (WLE), there is less consensus to support its use after oncoplastic breast-conserving surgery (OPBCS), which can reduce the need for mastectomy (Mx) and is gradually adopted as standard of care. The study aim was to assess if guidelines or individualized assessment result in optimal selection of patients for upfront SLNB. Methods: A panel of 28 international experts (20 surgeons, 8 oncologists, Europe 20, USA 5, Asia/Australia 3) was formed, all blind to the identity of the others. They reviewed anonymized patient cases from the SentiNot study (n=184, m. age 60 years, DCIS m. size 4 cm, Grade 2/3= 36%/64%, mass lesions 13,4%, underlying invasion 24.5%) and answer if they would consider upfront SLNB and why. Consensus and majority were set to >75 and >50%. At the same time, 6 independent raters (4 surgeons, 2 oncologists) reviewed guidelines and assessed the same patient cases per each guideline. Accuracy in relation to underlying invasion was assessed by Receiver Operating Characteristic (ROC) curves and Area Under the Curve (AUC) was reported. Agreement was investigated by kappa statistics and decision-making patterns by logistic multivariate regression and cluster analysis. To allow for flexibility and adaptation to current knowledge, both a frequentist and a Bayesian approach were undertaken. Priors were adjusted after a literature review regarding the factors that are commonly thought to be associated with higher risk for underlying invasion. Results: A total of 44,896 decisions were retrieved and analysed. The panel reached consensus/majority for upfront SLNB

Published
2020
Full Text
View/download PDF

43. Postdischarge pain, nausea and patient satisfaction after diagnostic and breast‐conserving ambulatory surgery for breast cancer: A cross‐sectional study.

Author

Stjernberg, Mi, Schlichting, Ellen, Rustoen, Tone, Valeberg, Berit T., Småstuen, Milada C., and Raeder, Johan C.

Subjects
*AMBULATORY surgery, *BREAST cancer surgery, *LUMPECTOMY, *PATIENT satisfaction, *NAUSEA, *CROSS-sectional method
Abstract

Background: The aims of this study were to assess first day postdischarge pain, nausea and patient satisfaction in ambulatory breast cancer surgical patients, after diagnostic and breast conserving procedures. Methods: A total of 781 women, aged 18–85 years were included in this prospective, cross‐sectional study. All patients received standardized multimodal pain prophylaxis with paracetamol, COX‐II inhibitor, dexamethasone and wound infiltration with local anaesthetics. Nausea prophylaxis was provided with ondansetron. Most patients received general anaesthesia with propofol and remifentanil. Data were collected using a validated questionnaire during telephone follow‐up on the first postoperative day. Results: The response rate was 94.5%. NRS ≥ 4 was reported by 5.3% at rest, by 17% during activity and by 30.7% as the worst pain score. Young age was strongly associated with more pain both at rest, during activity and regarding worst pain since discharge. Postdischarge nausea was present in 17.8%, and vomiting in 1.2%. High pain score during activity and higher level of worst pain, were associated with nausea. There was no association between nausea and age, type of anaesthesia, surgical procedure or pain at rest. Patient satisfaction was high (97.8%–99.7%) regarding information, time for discharge and overall satisfaction. Conclusion: Pain scores and incidence of nausea were generally low on the day after surgery. Young age was a strong predictor for postdischarge pain. A high worst pain score and high pain score during the activity were associated with postdischarge nausea. Patient satisfaction was high. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

45. The landscape of cancer genes and mutational processes in breast cancer

Author

Stephens, Philip J., Tarpey, Patrick S., Davies, Helen, Van Loo, Peter, Greenman, Chris, Wedge, David C., Nik-Zainal, Serena, Martin, Sancha, Varela, Ignacio, Bignell, Graham R., Yates, Lucy R., Papaemmanuil, Elli, Beare, David, Butler, Adam, Cheverton, Angela, Gamble, John, Hinton, Jonathan, Jia, Mingming, Jayakumar, Alagu, Jones, David, Latimer, Calli, Lau, King Wai, McLaren, Stuart, McBride, David J., Menzies, Andrew, Mudie, Laura, Raine, Keiran, Rad, Roland, Spencer Chapman, Michael, Teague, Jon, Easton, Douglas, Langerød, Anita, Karesen, Rolf, Schlichting, Ellen, Naume, Bjorn, Sauer, Torill, Ottestad, Lars, Lee, Ming Ta Michael, Shen, Chen-Yang, Tee, Benita Tan Kiat, Huimin, Bernice Wong, Broeks, Annegien, Vargas, Ana Cristina, Turashvili, Gulisa, Martens, John, Fatima, Aquila, Miron, Penelope, Chin, Suet-Feung, Thomas, Gilles, Boyault, Sandrine, Mariani, Odette, Lakhani, Sunil R., van de Vijver, Marc, van ‘t Veer, Laura, Foekens, John, Desmedt, Christine, Sotiriou, Christos, Tutt, Andrew, Caldas, Carlos, Reis-Filho, Jorge S., Aparicio, Samuel A. J. R., Salomon, Anne Vincent, Børresen-Dale, Anne-Lise, Richardson, Andrea L., Campbell, Peter J., Futreal, Andrew P., and Stratton, Michael R.

Published
2012
Full Text
View/download PDF

47. DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables

Author

Kamalakaran, Sitharthan, Varadan, Vinay, Giercksky Russnes, Hege E., Levy, Dan, Kendall, Jude, Janevski, Angel, Riggs, Michael, Banerjee, Nilanjana, Synnestvedt, Marit, Schlichting, Ellen, Kåresen, Rolf, Prasada, Shama K., Rotti, Harish, Rao, Ramachandra, Rao, Laxmi, Eric Tang, Man-Hung, Satyamoorthy, K., Lucito, Robert, Wigler, Michael, Dimitrova, Nevenka, Naume, Bjorn, Borresen-Dale, Anne-Lise, and Hicks, James B.

Published
2011
Full Text
View/download PDF

48. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk

Author

Kramer, Iris, primary, Hooning, Maartje J., additional, Mavaddat, Nasim, additional, Hauptmann, Michael, additional, Keeman, Renske, additional, Steyerberg, Ewout W., additional, Giardiello, Daniele, additional, Antoniou, Antonis C., additional, Pharoah, Paul D.P., additional, Canisius, Sander, additional, Abu-Ful, Zumuruda, additional, Andrulis, Irene L., additional, Anton-Culver, Hoda, additional, Aronson, Kristan J., additional, Augustinsson, Annelie, additional, Becher, Heiko, additional, Beckmann, Matthias W., additional, Behrens, Sabine, additional, Benitez, Javier, additional, Bermisheva, Marina, additional, Bogdanova, Natalia V., additional, Bojesen, Stig E., additional, Bolla, Manjeet K., additional, Bonanni, Bernardo, additional, Brauch, Hiltrud, additional, Bremer, Michael, additional, Brucker, Sara Y., additional, Burwinkel, Barbara, additional, Castelao, Jose E., additional, Chan, Tsun L., additional, Chang-Claude, Jenny, additional, Chanock, Stephen J., additional, Chenevix-Trench, Georgia, additional, Choi, Ji-Yeob, additional, Clarke, Christine L., additional, Collée, J. Margriet, additional, Couch, Fergus J., additional, Cox, Angela, additional, Cross, Simon S., additional, Czene, Kamila, additional, Daly, Mary B., additional, Devilee, Peter, additional, Dörk, Thilo, additional, dos-Santos-Silva, Isabel, additional, Dunning, Alison M., additional, Dwek, Miriam, additional, Eccles, Diana M., additional, Evans, D. Gareth, additional, Fasching, Peter A., additional, Flyger, Henrik, additional, Gago-Dominguez, Manuela, additional, García-Closas, Montserrat, additional, García-Sáenz, José A., additional, Giles, Graham G., additional, Goldgar, David E., additional, González-Neira, Anna, additional, Haiman, Christopher A., additional, Håkansson, Niclas, additional, Hamann, Ute, additional, Hartman, Mikael, additional, Heemskerk-Gerritsen, Bernadette A.M., additional, Hollestelle, Antoinette, additional, Hopper, John L., additional, Hou, Ming-Feng, additional, Howell, Anthony, additional, Ito, Hidemi, additional, Jakimovska, Milena, additional, Jakubowska, Anna, additional, Janni, Wolfgang, additional, John, Esther M., additional, Jung, Audrey, additional, Kang, Daehee, additional, Kets, C. Marleen, additional, Khusnutdinova, Elza, additional, Ko, Yon-Dschun, additional, Kristensen, Vessela N., additional, Kurian, Allison W., additional, Kwong, Ava, additional, Lambrechts, Diether, additional, Le Marchand, Loic, additional, Li, Jingmei, additional, Lindblom, Annika, additional, Lubiński, Jan, additional, Mannermaa, Arto, additional, Manoochehri, Mehdi, additional, Margolin, Sara, additional, Matsuo, Keitaro, additional, Mavroudis, Dimitrios, additional, Meindl, Alfons, additional, Milne, Roger L., additional, Mulligan, Anna Marie, additional, Muranen, Taru A., additional, Neuhausen, Susan L., additional, Nevanlinna, Heli, additional, Newman, William G., additional, Olshan, Andrew F., additional, Olson, Janet E., additional, Olsson, Håkan, additional, Park-Simon, Tjoung-Won, additional, Peto, Julian, additional, Petridis, Christos, additional, Plaseska-Karanfilska, Dijana, additional, Presneau, Nadege, additional, Pylkäs, Katri, additional, Radice, Paolo, additional, Rennert, Gad, additional, Romero, Atocha, additional, Roylance, Rebecca, additional, Saloustros, Emmanouil, additional, Sawyer, Elinor J., additional, Schmutzler, Rita K., additional, Schwentner, Lukas, additional, Scott, Christopher, additional, See, Mee-Hoong, additional, Shah, Mitul, additional, Shen, Chen-Yang, additional, Shu, Xiao-Ou, additional, Siesling, Sabine, additional, Slager, Susan, additional, Sohn, Christof, additional, Southey, Melissa C., additional, Spinelli, John J., additional, Stone, Jennifer, additional, Tapper, William J., additional, Tengström, Maria, additional, Teo, Soo Hwang, additional, Terry, Mary Beth, additional, Tollenaar, Rob A.E.M., additional, Tomlinson, Ian, additional, Troester, Melissa A., additional, Vachon, Celine M., additional, van Ongeval, Chantal, additional, van Veen, Elke M., additional, Winqvist, Robert, additional, Wolk, Alicja, additional, Zheng, Wei, additional, Ziogas, Argyrios, additional, Easton, Douglas F., additional, Hall, Per, additional, Schmidt, Marjanka K., additional, Børresen-Dale, Anne-Lise, additional, Sahlberg, Kristine, additional, Ottestad, Lars, additional, Kåresen, Rolf, additional, Schlichting, Ellen, additional, Holmen, Marit Muri, additional, Sauer, Toril, additional, Haakensen, Vilde, additional, Engebråten, Olav, additional, Naume, Bjørn, additional, Fosså, Alexander, additional, Kiserud, Cecile, additional, Reinertsen, Kristin, additional, Helland, Åslaug, additional, Riis, Margit, additional, Geisler, Jürgen, additional, Alnæs, Grethe Grenaker, additional, Clarke, Christine, additional, Marsh, Deborah, additional, Scott, Rodney, additional, Baxter, Robert, additional, Yip, Desmond, additional, Carpenter, Jane, additional, Davis, Alison, additional, Pathmanathan, Nirmala, additional, Simpson, Peter, additional, Graham, J. Dinny, additional, Sachchithananthan, Mythily, additional, Amor, David, additional, Andrews, Lesley, additional, Antill, Yoland, additional, Balleine, Rosemary, additional, Beesley, Jonathan, additional, Bennett, Ian, additional, Bogwitz, Michael, additional, Botes, Leon, additional, Brennan, Meagan, additional, Brown, Melissa, additional, Buckley, Michael, additional, Burke, Jo, additional, Butow, Phyllis, additional, Caldon, Liz, additional, Campbell, Ian, additional, Chauhan, Deepa, additional, Chauhan, Manisha, additional, Christian, Alice, additional, Cohen, Paul, additional, Colley, Alison, additional, Crook, Ashley, additional, Cui, James, additional, Cummings, Margaret, additional, Dawson, Sarah-Jane, additional, deFazio, Anna, additional, Delatycki, Martin, additional, Dickson, Rebecca, additional, Dixon, Joanne, additional, Edkins, Ted, additional, Edwards, Stacey, additional, Farshid, Gelareh, additional, Fellows, Andrew, additional, Fenton, Georgina, additional, Field, Michael, additional, Flanagan, James, additional, Fong, Peter, additional, Forrest, Laura, additional, Fox, Stephen, additional, French, Juliet, additional, Friedlander, Michael, additional, Gaff, Clara, additional, Gattas, Mike, additional, George, Peter, additional, Greening, Sian, additional, Harris, Marion, additional, Hart, Stewart, additional, Hayward, Nick, additional, Hopper, John, additional, Hoskins, Cass, additional, Hunt, Clare, additional, James, Paul, additional, Jenkins, Mark, additional, Kidd, Alexa, additional, Kirk, Judy, additional, Koehler, Jessica, additional, Kollias, James, additional, Lakhani, Sunil, additional, Lawrence, Mitchell, additional, Lindeman, Geoff, additional, Lipton, Lara, additional, Lobb, Liz, additional, Mann, Graham, additional, McLachlan, Sue Anne, additional, Meiser, Bettina, additional, Milne, Roger, additional, Nightingale, Sophie, additional, O'Connell, Shona, additional, O'Sullivan, Sarah, additional, Ortega, David Gallego, additional, Pachter, Nick, additional, Patterson, Briony, additional, Pearn, Amy, additional, Phillips, Kelly, additional, Pieper, Ellen, additional, Rickard, Edwina, additional, Robinson, Bridget, additional, Saleh, Mona, additional, Salisbury, Elizabeth, additional, Saunders, Christobel, additional, Saunus, Jodi, additional, Scott, Clare, additional, Sexton, Adrienne, additional, Shelling, Andrew, additional, Southey, Melissa, additional, Spurdle, Amanda, additional, Taylor, Jessica, additional, Taylor, Renea, additional, Thorne, Heather, additional, Trainer, Alison, additional, Tucker, Kathy, additional, Visvader, Jane, additional, Walker, Logan, additional, Williams, Rachael, additional, Winship, Ingrid, additional, and Young, Mary Ann, additional

Published
2020
Full Text
View/download PDF

50. Dietary changes in early-stage breast cancer patients from pre-surgery and over the 12 months post-surgery

Author

Brunvoll, Sonja H., primary, Thune, Inger, additional, Bertheussen, Gro F., additional, Fjeldheim, Frøydis, additional, Flote, Vidar G., additional, Frydenberg, Hanne, additional, Lundgren, Steinar, additional, Skjerven, Helle, additional, Lømo, Jon, additional, Fagerland, Morten W., additional, McTiernan, Anne, additional, Schlichting, Ellen, additional, and Hjartåker, Anette, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results